<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025038</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01861</org_study_id>
    <secondary_id>AAML0122</secondary_id>
    <secondary_id>U10CA098543</secondary_id>
    <secondary_id>CDR0000068788</secondary_id>
    <nct_id>NCT00025038</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia</brief_title>
  <official_title>Phase II Window Evaluation of the Farnesyl Transferase Inhibitor (R115777) Followed by 13-CIS Retinoic Acid, Cytosine Arabinoside and Fludarabine Plus Hematopoietic Stem Cell Transplantation in Children With Juvenile Myelomonocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Giving chemotherapy drugs, such as R115777, isotretinoin, cytarabine, and fludarabine, before
      a donor bone marrow transplant or an umbilical cord transplant helps stop the growth of
      cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem
      cells. When the healthy stem cells from a donor are infused into the patient they may help
      the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
      This phase II trial is studying how well giving combination chemotherapy together with donor
      bone marrow or umbilical cord blood transplant works in treating children with newly
      diagnosed juvenile myelomonocytic leukemia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the response rate of children with newly diagnosed juvenile myelomonocytic
      leukemia treated with R115777, isotretinoin, cytarabine, and fludarabine followed by
      allogeneic bone marrow or umbilical cord blood transplantation.

      II. Determine the safety and toxicity of this regimen in these patients. III. Determine the
      tolerability of this regimen in these patients. IV. Determine the rate of 2-year event-free
      survival of patients treated with this regimen.

      V. Determine whether prognostic subsets of these patients can be identified based on
      expression of clinical, genetic (NFI, monosomy 7, RAS gene), or hematopoietic
      characteristics.

      OUTLINE: This is a multicenter study.

      Patients may choose to receive upfront window induction therapy with oral R115777 twice daily
      on days 1-21. Treatment repeats every 28 days for 2 courses in the absence of disease
      progression or unacceptable toxicity.

      Patients with progressive disease or stable disease with unacceptable hematopoietic recovery
      after 1 course proceed to induction chemotherapy. (R11577 portion of the study closed to
      accrual as of 08/2005)

      All patients receive induction chemotherapy comprising oral isotretinoin once daily beginning
      on day 1 and fludarabine IV over 30 minutes and cytarabine IV over 4 hours on days 1-5.
      Treatment with fludarabine and cytarabine repeats every 28 days for 2 courses. Treatment with
      isotretinoin continues until allogeneic bone marrow or umbilical cord blood transplantation.
      Patients with progressive disease after 1 course proceed to transplantation.

      After completion of isotretinoin, patients receive a preparative regimen comprising total
      body irradiation twice daily on days -7 to -4, cyclophosphamide IV over 2 hours on days -3
      and -2, and anti-thymocyte globulin IV over 4-6 hours every 12 hours on days -3 to -1.
      Patients undergo allogeneic bone marrow or umbilical cord blood transplantation on day 0.
      Patients receive oral isotretinoin daily beginning on approximately day 60 and continuing for
      1 year.

      Patients are followed every 6 months for 5 years and then annually thereafter.

      PROJECTED ACCRUAL: A maximum of 100 patients (18-46 receiving R115777 with induction
      chemotherapy [R11577 portion of the study closed to accrual as of 08/2005] and 27-54
      receiving induction chemotherapy only) will be accrued for this study within 3.2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (CR or PR)</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>The response rates in the up-front window with respect to whether or not patients had vas activating mutations will also be estimated by proportions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Will be estimated by Kaplan-Meier method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Will be estimated by Kaplan-Meier method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of prognostic importance of genetic marker</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Logrank test and Cox proportional hazards model will be applied.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade 3 or greater toxicities assessed using CTC version 2.0</measure>
    <time_frame>Up to 6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival of patients receiving the window vs. not</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response status on end of course reports (pre vs.post)</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Signed-rank comparison of components of therapy will be done.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Juvenile Myelomonocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (tipifarnib, bone marrow/umbilical cord transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See detailed description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tipifarnib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (tipifarnib, bone marrow/umbilical cord transplant)</arm_group_label>
    <other_name>R115777</other_name>
    <other_name>Zarnestra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isotretinoin</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (tipifarnib, bone marrow/umbilical cord transplant)</arm_group_label>
    <other_name>13-CRA</other_name>
    <other_name>Amnesteem</other_name>
    <other_name>Cistane</other_name>
    <other_name>Claravis</other_name>
    <other_name>Sotret</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tipifarnib, bone marrow/umbilical cord transplant)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tipifarnib, bone marrow/umbilical cord transplant)</arm_group_label>
    <other_name>ARA-C</other_name>
    <other_name>arabinofuranosylcytosine</other_name>
    <other_name>arabinosylcytosine</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>cytosine arabinoside</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Undergo total body irradiation</description>
    <arm_group_label>Treatment (tipifarnib, bone marrow/umbilical cord transplant)</arm_group_label>
    <other_name>irradiation</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>therapy, radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tipifarnib, bone marrow/umbilical cord transplant)</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tipifarnib, bone marrow/umbilical cord transplant)</arm_group_label>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>lymphocyte immune globulin</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
    <description>Undergo allogeneic bone marrow transplant</description>
    <arm_group_label>Treatment (tipifarnib, bone marrow/umbilical cord transplant)</arm_group_label>
    <other_name>bone marrow therapy, allogeneic</other_name>
    <other_name>bone marrow therapy, allogenic</other_name>
    <other_name>transplantation, allogeneic bone marrow</other_name>
    <other_name>transplantation, allogenic bone marrow</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>double-unit umbilical cord blood transplantation</intervention_name>
    <arm_group_label>Treatment (tipifarnib, bone marrow/umbilical cord transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
    <description>Undergo allogeneic cord blood transplant</description>
    <arm_group_label>Treatment (tipifarnib, bone marrow/umbilical cord transplant)</arm_group_label>
    <other_name>cord blood transplantation</other_name>
    <other_name>transplantation, umbilical cord blood</other_name>
    <other_name>UCB transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (tipifarnib, bone marrow/umbilical cord transplant)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed, previously untreated juvenile myelomonocytic leukemia

          -  Presenting with all of the following:

               -  Absence of t(9;22) or bcr/abl by PCR

               -  Absolute monocyte count greater than 1,000/mm^3

               -  Less than 20% bone marrow blasts

          -  Presenting with at least 2 of the following:

               -  Elevated F hemoglobin

               -  Myeloid precursors in peripheral blood

               -  WBC greater than 10,000/mm^3

               -  Sargramostim (GM-CSF) hypersensitivity

          -  See Disease Characteristics

          -  Bilirubin no greater than 2.0 mg/dL

          -  ALT no greater than 3 times normal

          -  Creatinine no greater than 2 times normal

          -  No concurrent sargramostim (GM-CSF)

          -  No concurrent proton pump inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Castleberry</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Oncology Group</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 10, 2013</last_update_submitted>
  <last_update_submitted_qc>April 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Tipifarnib</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

